Fig. 6: A schematic representation of MYSM1-mediated RSK3 expression and cisplatin resistance.
From: MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway
Upon cisplatin treatment on TNBC cells, MYSM1 represses RSK3 expression, and reduces the phosphorylation of BAD at Ser 112, leading to cell apoptosis and cisplatin sensitivity.
